title: [Multidisciplinary approach to the treatment of rectal cancer: the benefits of neoadjuvant therapy].
abstract: OBJECTIVE
  the aim of this study was to assess the impact of neoadjuvant treatment on rectal cancer following involvement of a multidisciplinary team (MDT).
  
  
  METHODS
  between January 2000 and December 2005, 90 patients with rectal adenocarcinoma were evaluated by a MDT and operated on after receiving neoadjuvant treatment with radiochemotherapy (RTCT) -67% were men and 33% were women, with a mean age of 65.04 years (21-83 years). Surgery was low anterior resection in 50% and abdominoperineal amputation in 42.2%.
  
  
  RESULTS
  the rate of complications associated with neoadjuvant treatment was 54.4%, with gastrointestinal complications being most frequent. However, this toxicity was tolerated by most patients. It was severe in two cases (2.2%), leading to chemotherapy discontinuation. A histological analysis of specimens showed a complete pathologic response in 10 cases (11.1%) and a partial response (downstaging of T) in 32 cases (35.6%), hence overall response to neoadjuvant treatment was 46.6%. Postoperative complications included anastomotic leakage in 8.3%, perineal wound complications in 34.2%, and urinary disease in 12.2%. The surgical mortality rate was 0%. Local recurrence occurred in 4.4%, and distant metastases were found in 22.2%. Both overall and disease-free survivals were 80 and 64%, respectively.
  
  
  CONCLUSIONS
  neoadjuvant treatment results in low local recurrence rates and optimal survival rates, with no increase in morbidity or mortality. A systematic evaluation by a MDT in the context of a clinical protocol offers better cure rates.
authors.affiliation: Departamento de Cirugía General y Digestivo. Hospital Universitario Ramón y Cajal, Madrid, Spain. papriego@hotmail.com
authors.forename: P
authors.initials: P
authors.lastname: Priego
authors.forename: A
authors.initials: A
authors.lastname: Sanjuanbenito
authors.forename: V
authors.initials: V
authors.lastname: Morales
authors.forename: E
authors.initials: E
authors.lastname: Lobo
authors.forename: E
authors.initials: E
authors.lastname: Martínez Molina
authors.forename: G
authors.initials: G
authors.lastname: Rodríguez Velasco
authors.forename: V
authors.initials: V
authors.lastname: Fresneda
mesh_terms: D000230:Adenocarcinoma / Q000401:mortality / Q000628:therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D010348:Patient Care Team; D012004:Rectal Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D055815:Young Adult